NeuroSense Therapeutics L... (NRSNW)
0.45
-0.06 (-11.76%)
At close: Jan 14, 2025, 1:49 PM
0.45
0.00%
After-hours Jan 14, 2025, 01:49 PM EST
undefined% (undefined)
| Bid | 0.12 |
| Market Cap | 21.22M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -0.935 |
| PE Ratio (ttm) | -0.48 |
| Forward PE | n/a |
| Analyst | n/a |
| Ask | n/a |
| Volume | 4,622 |
| Avg. Volume (20D) | 0 |
| Open | 0.63 |
| Previous Close | 0.51 |
| Day's Range | 0.31 - 0.67 |
| 52-Week Range | 0.31 - 0.67 |
| Beta | undefined |
About NRSNW
NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for debilitating neurodegenerative diseases in Israel. Its lead product candidate is PrimeC, a novel oral formulation for the treatment of amyotrophic lateral sclerosis. The company's preclinical pipeline product candidates include StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's dise...
Industry Biotechnology
Sector Healthcare
IPO Date n/a
Employees 18
Stock Exchange NASDAQ
Ticker Symbol NRSNW
Website https://www.neurosense-tx.com